Karyopharm Therapeutics reported $58.12M in Current Liabilities for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Liabilities Change
Acceleron Pharma XLRN:US $ 59.48M 9.66M
Amgen AMGN:US $ 14585M 1716M
AstraZeneca AZN:LN 22222M 709M
Astrazeneca AZN:US $ 22222M 709M
Avrobio Inc AVRO:US $ 16.95M 4.18M
Bristol Myers Squibb BMY:US $ 18991M 1661M
Eli Lilly And LLY:US $ 15093.2M 3379M
Enanta Pharmaceuticals ENTA:US $ 28.62M 2.01M
Epizyme EPZM:US $ 40.89M 1.89M
GlaxoSmithKline GSK:LN 21387M 1112M
Karyopharm Therapeutics KPTI:US $ 58.12M 3.88M
Macrogenics MGNX:US $ 69.92M 16.88M
Mirati Therapeutics MRTX:US $ 180.87M 103.76M
Nektar Therapeutics NKTR:US $ 131.02M 7.39M
Novartis NOVN:VX SF 29633M 527M
Novartis NVS:US $ 29633M 527M
Regeneron Pharmaceuticals REGN:US $ 3732.4M 514.6M
Sangamo Biosciences SGMO:US $ 136.94M 4.1M
Takeda 4502:JP Y 1644766M 128410M
Ultragenyx Pharmaceutical RARE:US $ 127.07M 0.02M
Xencor XNCR:US $ 45.96M 53.97M
YTE INCY:US $ 660.32M 36.44M